The TruCheck test does not detect all cancer types and not all cancer types can be detected in the blood. False negative and false positive results do occur.


TruCheck identifies a common cancer signal across numerous cancer types, inclusive of those not routinely screened in today’s practice, enabling treatment at earlier stages.

The test only requires a single blood draw. We will arrange a trained professional to visit you to take a sample. We make the process as simple and convenient as possible.

TruCheck is an advanced non-invasive blood test which provides evidence of an underlying malignancy via a safe, simple and quick blood draw. TruCheck evaluates blood sample to detect ‘Circulating Tumour Cells’ (CTCs), which are cancer cells that escape from the tumour and enter the blood stream. TruCheck enriches these CTCs from the blood sample and confirms their identity via a process called ‘Immunocytochemistry’ (ICC). A positive CTC finding is indicative of the presence of an underlying cancer whereas when CTCs are undetectable, the patient may not have a cancer.


You can start by requesting the test online by clicking Get Started. You will be guided through a number of questions to determine your eligibility for the test. Your request will then be reviewed to ensure that the test is suitable for you.


Results are usually emailed within 10–15 working days of your sample reaching the laboratory. We will provide guidance on your next steps if you receive a positive result.
There are three possible results:
– Positive for malignancy: CTCs were detected in the blood sample. The analysis suggests the likely organ of origin and malignancy type.
– Negative for malignancy: CTCs are not detected in the given sample. The chance of
having an active malignancy present in the body is low.
– Indeterminate: CTCs were detected in the given blood sample; however, type of malignancy or organ of origin could not be determined. A recollection of a blood sample is required to determine result (free of charge).
Please note, TruCheck is a screening test and does not diagnose cancer itself. While it offers a ground-breaking tool for early detection, additional diagnostic testing is necessary to confirm a cancer diagnosis. Furthermore, TruCheck is not a genetic risk assessment tool and does not predict future risk of developing cancer. It operates by detecting existing cancer signals, not potential genetic predispositions.

The TruCheck test is for adults aged 40 or over (35–39 if at higher risk, on enquiry) who have no symptoms of cancer. TruCheck does not detect all types of cancers and should be considered a supplemental tool alongside routine cancer screening tests advised by your healthcare provider. The primary goal of TruCheck is to identify cancer signals and predict their origin within the body. It is not recommended for use in individuals who are pregnant or currently undergoing active cancer treatment.
Results must be analysed by a healthcare professional, taking into account the patient’s medical history, clinical signs, and symptoms. A result of “No Cancer Signal Detected” does not definitively exclude the presence of cancer. Likewise, a “Cancer Signal Detected” result necessitates further diagnostic evaluation through established medical procedures (such as imaging) to confirm the presence of cancer.
In cases where further testing does not confirm cancer, this could indicate either the absence of cancer or that the test was unable to detect it, including situations where the cancer is located in a different part of the body. Be aware that false-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) results can occur.
1. Akolkar et al. B15: Circulating tumor cells express tissue specific antigens in multiple cancers. Clin Cancer Res.2020;
26(11_Suppl). DOI: 10.1158/1557-3265.LiqBiop20-B15.
2. Akolkar et al. Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. Int. J.
Cancer:2019; 146, 3485-3494. DOI: 10.1002/ijc.32815.
3. Gaya A et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol.
2020; 129 (3) 226-238 doi: 10.1002/cncy.22366.
4. Ranade A et al. Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer
Prev Res. 2021;14:11-6 DOI:10.1158/1940-6207.CAPR-20-0322.
5. Crook T et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers
(Basel). 2022 Jul; 14(14): 3341. DOI: 10.3390/cancers14143341.